会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 1941, 19310, or 17832
    • 使用232,2059,10630,12848,13875,14395,14618,17782,58874,252,304,1980,14717,9941,1941,199310或17832来治疗血液病症的方法和组合物
    • US20060099656A1
    • 2006-05-11
    • US11242505
    • 2005-10-03
    • Joseph CarrollAileen Healy
    • Joseph CarrollAileen Healy
    • G01N33/567
    • G01N33/6893G01N2800/22Y02A50/58
    • The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692, 58874, 252, 304, 1980, 14717, 9941, 19310, or 17832 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.
    • 本发明涉及诊断和治疗血液学疾病的方法。 具体地,本发明鉴定了与血液学疾病感觉有关的组织中的232,2059,10630,12848,13875,14395,14618,17712,58874,252,304,1980,14717,9941,19310或17832基因的差异表达 相对于它们在正常或非血液学疾病疾病状态中的表达,和/或响应于与血液学疾病相关的操作。 本发明描述了各种血液学疾病的诊断评价和预后的方法,以及用于鉴定表现出对这种病症倾向的受试者。 本发明还提供了鉴定能够调节血液学疾病的化合物的方法。 本发明还提供了用于鉴定和治疗化合物作为血液学疾病治疗的方法。
    • 7. 发明申请
    • RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
    • US20070185049A1
    • 2007-08-09
    • US11592039
    • 2006-11-02
    • Vasant JadhavJoseph Carroll
    • Vasant JadhavJoseph Carroll
    • A61K48/00C07H21/02
    • C12N15/1137A61K48/00C07H21/02C12N2310/14C12N2310/318C12N2310/321C12N2310/53C12N2310/3521
    • The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, disease and conditions that respond to the modulation of histone deacetylase (HDAC) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in HDAC gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating or that mediate RNA interference (RNAi) against HDAC gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous HDAC micro-RNA (miRNA) (e.g., miRNA inhibitors) or endogenous HDAC short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate HDAC gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions for treatment of traits, diseases and conditions that can respond to modulation of HDAC gene expression in a subject or organism, such as cancer and other proliferative diseases or conditions that are associated with HDAC gene expression or activity.